Research programme: selective estrogen receptor modulators - SignalGene
Alternative Names: Selective estrogen receptor modulators research programme - SignalGeneLatest Information Update: 02 Oct 2021
At a glance
- Originator SignalGene [CEASED]
- Class
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 07 Aug 2003 SignalGene has ceased its pharmaceutical operations
- 07 Aug 2003 Discontinued - Preclinical for Breast cancer in Canada (unspecified route)
- 07 Aug 2003 Discontinued - Preclinical for Menopausal syndrome in Canada (unspecified route)